Dr. John E. Niederhuber Appointed Chairman of Konica Minolta’s Scientific Advisory Board
ALISO VIEJO, Calif. (PRWEB) July 27, 2018 -- Konica Minolta Precision Medicine Inc., a newly formed division of Konica Minolta focused on revolutionizing personalized patient care, announced today the appointment of Dr. John E. Niederhuber as the Chairman of their Scientific Advisory Board.
Late last year, Konica Minolta acquired Ambry Genetics, a leader in genetic diagnostics, and Invicro, a leading provider of quantitative biomarker profiling services. These symbiotic technologies can facilitate faster drug discovery for targeted therapies, ushering in a new era of personalized medicine. Combined with Konica Minolta’s original immunohistochemistry technology, Konica Minolta now brings to the market a comprehensive precision medicine offering, leveraging a powerful blend of genomics, proteomics and imaging expertise. With Dr. Niederhuber’s appointment as Scientific Advisory Board Chairman, his thought leadership and vision will drive this patient-centric mission.
Previously, Dr. Niederhuber served as the Director of the National Cancer Institute, National Institutes of Health, and currently serves as the Executive Vice President and CEO of Inova Translational Medicine Institute (ITMI) and is the newly appointed President and CEO of the Genomics and Bioinformatics Research Institute (GBRI), a new research institute jointly funded by the University of Virginia and the Inova Health System. He is also a Professor of Public Health Sciences at the University of Virginia School of Medicine, Adjunct Professor of Oncology and Surgery at Johns Hopkins University School of Medicine, and Deputy Director of the Johns Hopkins Clinical Research Network.
Dr. Niederhuber has dedicated his highly successful career to the study and treatment of cancer. As a child growing up in a small steel mill town in Ohio, he was inspired by the local doctor who often made house calls on his way home, understanding then the value of personalized patient care. Dr. Niederhuber passionately believes that the precise blending of oncology, radiation, imaging and pathology offers the best solutions for complex diseases like cancer, by matching more patients to more effective therapies.
As Chairman of Konica Minolta’s Scientific Advisory Board, Dr. Niederhuber will provide critical input on Konica Minolta’s business development initiatives related to their genetic testing portfolio, biopharma services, and comprehensive imaging capabilities. Dr. Niederhuber will also guide their research initiatives and collaborations, further positioning Konica Minolta as a global leader focused on advancing precision medicine and improving patient outcomes.
“We are fortunate to have Dr. Niederhuber, a leader in the global oncology space, to serve as Chairman of our Scientific Advisory board,” said Kiyotaka Fujii, President Global Healthcare, Konica Minolta. “Dr. Niederhuber’s vision and thought leadership will provide unique insights on how to position Konica Minolta’s high quality genomic capabilities, fuel our research and move us closer to the reality of precision medicine.”
"I am excited to take on this new role and leverage Konica Minolta’s experience and breadth of diagnostic technologies,” said Dr. Niederhuber. “The medical oncology space is rapidly evolving and synergistic technologies such as theirs are vital to better understand disease and improve patient outcomes.”
About Ambry
Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry is an established leader in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit http://www.ambrygen.com
About Invicro
Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017. Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, has inspired a strong and growing presence in the market. For more information, visit http://www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: http://www.konicaminolta.com
Press Contact:
Dina Scaglione
Director, Marketing
dscaglione(at)ambrygen(dot)com
949 457 4355
Dina Scaglione, Ambry Genetics, https://www.ambrygen.com/, +1 949-457-4355, [email protected]
Share this article